Part fund, part accelerator, Contrary Capital invests in student entrepreneurs

First Round Capital has both the Dorm Room Fund and the Graduate Fund. General Catalyst has Rough Draft Ventures. And Prototype Capital and a few other micro-funds focus on investing in student founders, but overall, there’s a shortage of capital set aside for entrepreneurs still making their way through school. Contrary Capital, a soon-to-be San Francisco-based operation led by Eric Tarczynski, is raising $35 million to invest between $50,000 and $200,000 in students and recent college dropouts. The firm, which operates a summer accelerator program for its portfolio companies, closed on $2.2 million for its debut, proof-of-concept fund in 2018. Contrary Capital celebrating its Demo Day event last year Last year, Contrary kicked off its summer accelerator, tapping 10 university-started …

A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing

This morning, a publicly traded transplant diagnostics company called CareDx, along with Stanford University, sued another publicly traded genetic testing company, Natera, for patent infringement. Much appears to be at stake, and it all centers on cell-free DNA testing, a type of technology that has already been at the crux of numerous lawsuits and looks poised to play center stage again in future corporate battles. Loosely defined, cell-free DNA (or cfDNA) technology involves blood tests that enable physicians to understand what’s happening in someone’s body. They’re not looking at red or white blood cells (thus the “cell free” part) but at plasma, which carries pieces of broken-up DNA, among other things. Companies like newly public Guardant Health are using it …